Chemours Co (CC) — Insider Trading

AI-Powered SEC Filing Analysis

Latest Insider Trading Filed: 2026-05-08

Key Insights

Director Mary B. Cranston acquired 7,182 shares of common stock on 05/06/2026 at $0 price, indicating this was likely a compensation award rather than a market purchase.
The filing notes an administrative correction to prior Form 4s, with total holdings adjusted to 106,830.0129 shares including deferred stock units and dividend equivalent units, suggesting prior reporting discrepancies that have now been reconciled.
As a director-level insider, Cranston's acquisition through equity compensation (deferred stock units) reflects standard board compensation practices rather than voluntary market purchases, providing limited signal about management confidence in the stock.

Want the newest filings?

This analysis covers the filing from 2026-05-08. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Earlier Insider Trading filings

Filed: 2026-05-08

Director Leslie M Turner acquired 7,182 shares of Chemours common stock on 05/06/2026 with $0 consideration, indicating these were compensation-related stock units rather than open-market purchases.
Turner's total beneficial ownership increased to 24,603.3891 shares following the transaction, with the acquisition comprising deferred stock units and dividend equivalent units that convert upon board separation.
This transaction represents routine director compensation and does not signal material insider confidence or concern about the company's valuation, as the acquisition was non-discretionary equity compensation.

Filed: 2026-05-08

Director Pamela Fletcher acquired 7,182 shares of Chemours common stock on 05/06/2026 at no cost, representing stock units that convert upon separation from service, indicating this is a vesting/compensation event rather than open market buying.
Fletcher's total beneficial ownership increased to approximately 32,383 shares following the transaction, suggesting established accumulated equity compensation from her board service.
The transaction involves deferred stock units and dividend equivalent units, which are typical director compensation mechanisms that do not signal insider confidence or concern about company valuation.

Filed: 2026-05-08

Director Alister Cowan acquired 7,182 shares of common stock on 05/06/2026 at no cost, representing a vesting of restricted stock units rather than open market purchases.
Cowan's total beneficial ownership increased to approximately 43,881 shares following this transaction, indicating meaningful accumulated equity stake as a board member.
The acquisition was made pursuant to equity compensation rather than discretionary buying, suggesting this reflects normal director compensation practices rather than insider conviction about stock valuation.
The filing shows no derivative securities or options activity, indicating the transaction involved only restricted stock unit conversion upon service continuation.

Filed: 2026-05-08

Director Courtney Mather acquired 7,182 shares of common stock on 05/06/2026 at no cost, indicating a stock unit vesting event rather than open market purchase, suggesting compensation tied to board service.
Total beneficial ownership increased to 21,642.7173 shares following the transaction, with the acquisition comprised of deferred stock units and dividend equivalent units that convert upon separation from the board.
The filing represents a routine insider transaction typical of director compensation practices; the zero purchase price and vesting mechanism indicate this is part of standard equity compensation rather than a discretionary market transaction.
As a director-only position with no officer title, this transaction provides limited insight into management's confidence in company prospects, making it less significant than officer or substantial shareholder transactions.

Filed: 2026-05-08

Director Erin Kane acquired 7,182 shares of Chemours common stock on 05/06/2026 with zero purchase price, indicating this was a compensation-related transaction (likely restricted stock units vesting) rather than open market buying.
Kane's total beneficial ownership increased to approximately 74,063 shares following the transaction, with holdings comprised of deferred stock units and dividend equivalent units, showing long-term alignment with shareholder interests.
The transaction was executed through stock units that convert one-for-one upon separation from service on the Board, which is a standard equity compensation mechanism for directors but does not signal insider confidence in near-term stock appreciation.

Filed: 2026-05-08

Director Livingston acquired 7,182 shares of common stock on 05/06/2026 at $0 price, indicating these were received as compensation rather than a market purchase, reflecting standard director equity grants.
Total beneficial ownership following the transaction is 30,807.855 shares, comprised of direct holdings and deferred/dividend equivalent stock units that convert upon board separation, showing meaningful accumulated equity stake.
The filing documents a routine equity compensation event for a board director rather than a significant insider trading signal, as the $0 price and nature of restricted stock units are typical for director remuneration.

Filed: 2026-05-08

Director Sean D. Keohane acquired 7,182 shares of Chemours common stock on 05/06/2026 at no cost, representing a stock unit conversion upon vesting rather than open market purchase.
The acquisition increased Keohane's beneficial ownership to 72,555.1777 shares, indicating established and growing stake in the company as a board member.
The transaction involved deferred stock units and dividend equivalent units converting to common stock, a typical compensation mechanism for directors that aligns interests with shareholders but does not signal strong conviction buying.

Filed: 2026-05-08

Director Kava Joseph Daniel acquired 7,182 shares of Chemours common stock on 05/06/2026 through stock units that convert upon separation from service, bringing total beneficial ownership to 24,603.3891 shares.
The acquisition was made at $0 price, indicating this is a compensation-related grant or vesting of deferred stock units and dividend equivalent units rather than an open market purchase.
As a Director, this insider transaction represents routine equity compensation rather than discretionary buying activity, providing limited insight into management's confidence in the stock's future performance.
The filing is dated 2026-05-08, which is a future date, suggesting this is a hypothetical or test filing that should not be used for actual investment decisions.

Filed: 2026-05-08

Director George R. Brokaw acquired 7,182 shares of Chemours common stock on May 6, 2026 at $0 consideration, indicating this was a non-cash equity award (deferred stock units or dividend equivalent units) rather than a market purchase.
Following this transaction, Brokaw's total beneficial ownership increased to approximately 21,643 shares, demonstrating continued alignment with shareholder interests through equity compensation.
The use of a Rule 10b5-1 plan for this transaction suggests pre-planned, systematic equity accumulation by an insider, which is a compliance-positive indicator for insider trading rules.

Filed: 2026-04-01

Courtney Mather, a director of Chemours Co (CC), acquired 1,305 deferred stock units on March 31, 2026 at a price of $22.03 per unit.
This acquisition increases Mather's total beneficial ownership to 7,552.3528 units, representing a direct ownership stake in the company.
Insider buying can be a positive signal, indicating the director's confidence in the company's future prospects.

Filed: 2026-01-05

Courtney Mather, a director of Chemours Co (CC), acquired 2,226 deferred stock units on 2025-12-31, indicating continued confidence in the company's long-term prospects.
The deferred stock units will become payable upon Mather's termination of service as a director, aligning her interests with those of long-term shareholders.
The acquisition of the deferred stock units at a price of $11.79 per unit suggests Mather believes the stock is undervalued at current market prices.

Other reports for Chemours Co

Quarterly Report Current Report Annual Report

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.